Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage breast-cancer patients to receive neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive four additional AC cycles before surgery. A key feature is the incorporation of an response-guided neoadjuvant therapy（RGN）model to identify sensitive patients who can forgo anthracyclines, thereby reducing long-term cardiotoxicity.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjentka świadomie zgadza się na udział w badaniu i podpisuje zgodę.
- •Wiek od 18 do 75 lat.
- •Potwierdzony histopatologicznie wczesny potrójnie ujemny rak piersi.
- •Guz pierwotny o średnicy powyżej 2 cm.
- •Stan ogólny pozwalający na leczenie (ocena ECOG PS 0-1).
- •Pacjentka zgadza się na operację usunięcia guza po leczeniu przedoperacyjnym.
- •Pacjentka zgadza się na pobranie wycinków guza do analizy badawczej.
✗ Disqualifies
- •Pacjentki z przerzutowym rakiem piersi (stadium IV).
- •Inne choroby znacząco wpływające na zdrowie pacjentki lub możliwość leczenia (według oceny lekarza prowadzącego).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 28, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Trial contact
Yongsheng Jia, Doctor
Wenxiao Liu
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.